The Aristo Bio-Tech & Lifescience IPO is a closed SME Fixed Price offer (Fresh Capital) that opened on 16 January 2023. The Aristo Bio-Tech & Lifescience IPO closed on 19 January 2023, with an issue price of ₹72 per share. The Aristo Bio-Tech & Lifescience IPO has a face value of ₹10 and a lot size of 1,600 shares. The Aristo Bio-Tech & Lifescience IPO is listed on 30 January 2023. The Aristo Bio-Tech & Lifescience IPO allotment was scheduled for 24 January 2023.
On the financial front, the Aristo Bio-Tech & Lifescience IPO reported revenue of ₹12,907 for 30-Sep-22, compared with ₹16,603 for 31-Mar-22. The Aristo Bio-Tech & Lifescience IPO PAT was ₹259 against ₹146. The Aristo Bio-Tech & Lifescience IPO net worth as of 30-Sep-22 was ₹1,743.
Always verify The Aristo Bio-Tech & Lifescience IPO details and GMP data with the official offer document before investing in the Aristo Bio-Tech & Lifescience IPO.
Financial Summary
Amount in ₹ Lakhs
Metric
30-Sep-22
31-Mar-22
31-Mar-21
Total Assets
10,869
7,700
8,142
Revenue
12,907
16,603
16,723
PAT
259
146
108
Net Worth
1,743
1,484
1,338
Reserves
1,244
985
839
Total Borrowing
2,936
2,548
2,225
Aristo Bio-Tech & Lifescience IPO Financials FAQs
Revenue of Aristo Bio-Tech & Lifescience (Amount in ₹ Lakhs) — 30-Sep-22: 12,907; 31-Mar-22: 16,603; 31-Mar-21: 16,723. Profit after tax (PAT) — 30-Sep-22: 259; 31-Mar-22: 146; 31-Mar-21: 108.
Total borrowing of Aristo Bio-Tech & Lifescience (Amount in ₹ Lakhs) — 30-Sep-22: 2,936; 31-Mar-22: 2,548; 31-Mar-21: 2,225.
The financials shown for Aristo Bio-Tech & Lifescience IPO are taken from the company's offer document (DRHP/RHP/prospectus) filed with the exchange and SEBI, and are updated here when restated figures are published. Always cross-check with the official offer document before investing.
Look at the trend of revenue and PAT across periods, whether EBITDA is growing along with revenue, and whether net worth is rising while borrowings stay under control. The first column may be a part-year (interim) period, so compare full financial years with each other.
GMP and IPO data are unofficial and for information only — not investment advice.
Read the full disclaimer.
